Background Data: Hyperglycemia and accelerated muscle catabolism have been shown to adversely affect immune response and survival. The purpose of this study was to determine the effect of metformin on glucose kinetics and muscle protein metabolism in severely burned patients and assess any potential benefit of metformin in this clinical setting. Methods: In a double-blind, randomized manner, 8 adult burn patients received metformin (850 mg every 8 hours ϫ 7 days), while 5 burn patients received placebo. Infusions of 6,6d 2 glucose, d 5 phenylalanine, sequential muscle biopsies, and femoral arterial, venous blood sampling allowed determination of glucose and muscle protein kinetics. Measurements were obtained immediately prior and at the conclusion of 7 days of treatment (metformin versus placebo). All patients received enteral feeds of comparable amounts during study. Results: Patients receiving metformin had a significant decrease in their plasma glucose concentration, the rate of glucose production, and an increase in glucose clearance. Metformin administration was also associated with a significant increase in the fractional synthetic rate of muscle protein and improvement in net muscle protein balance. Glucose kinetics and muscle protein metabolism were not significantly altered in the patients receiving placebo. Conclusions: Metformin attenuates hyperglycemia and increases muscle protein synthesis in severely burned patients, thereby indicating a metabolic link between hyperglycemia and muscle loss following severe injury. Therefore, therapies that improve glucose tolerance such as metformin may be of clinical value in ameliorating muscle catabolism in critically injured patients. (Ann Surg 2005;241: 334 -342) 
G lucose intolerance and muscle catabolism are prominent components of the hypermetabolic response to severe injury. 1 These 2 metabolic events have a profound detrimental influence on immune function, wound healing, and adversely affect survival. 2, 3 For example, the adverse sequel of hyperglycemia in critically ill patients was clearly highlighted in a recent investigation by van den Berghe et al. 4 In this study, over 1500 surgical patients were randomized on entrance into the surgical intensive care unit to either conventional insulin therapy (designed to maintain plasma glucose values between 180 and 200 mg/dL) or intensive insulin therapy (with a target plasma glucose of 80 to 110 mg/dL). Despite a comparable severity of illness and patient demographics, mortality was 8% in those patients with a previously "acceptable" hyperglycemia compared with only 4% for those patients with aggressive correction to normal plasma glucose values. Intensive insulin therapy had its greatest influence on reducing the occurrence of bloodstream infections, decreasing the incidence of acute renal failure, significantly reducing the duration of mechanical ventilatory support and substantially decreasing death from sepsis-induced organ dysfunction. These findings demonstrated the detrimental effects of even "mild" hyperglycemia in severely ill, surgical patients.
Muscle loss also appears to have a substantial influence on the survival of critically ill patients. For example, a 15% loss of lean body mass correlates with an inhibition of T-cell-mediated immune response and corresponds clinically to significant increases in the number of infectious complications and substantial delays in wound healing. 5, 6 Muscle loss also affects strength. 7 Muscle weakness is of special concern in patients requiring mechanical ventilatory support in which a poor cough combined with depressed immune function breeds pneumonia. 8 Although anecdotal, it is a commonly held premise that the consequence of a 40% loss of lean body mass is probable death from pulmonary sepsis. 9 Further, severe muscle catabolism impairs functional recovery following discharge from the ICU. 10 In hypermetabolic, critically ill patients, resistance to the action of insulin may be a link metabolically between glucose intolerance and muscle protein catabolism. Prior work has shown a detriment in insulin receptor sensitivity as a prominent mechanism contributing to stress-induced hyperglycemia. 11, 12 Since insulin also functions physiologically to augment muscle protein synthesis, 13 it is conceivable that an illness-induced defect in insulin receptor sensitivity may also contribute to the net catabolism of muscle protein. Therefore, pharmacologic agents such as metformin, which improve insulin receptor sensitivity, may have a dual action of attenuating hyperglycemia and augmenting net muscle protein anabolism. 14, 15 Alternatively, a reduction in gluconeogenesis by metformin may reduce the consumption of alanine (a primary precursor) and decrease the requirement for amino acid oxidation to fuel the endogenous production of glucose. 16 The net effect may be a metformin-induced decrease in muscle protein breakdown. Metformin's action on augmenting peripheral glucose disposal may also increase energy availability in muscle tissue. This effect may further decrease muscle protein breakdown by a shift toward greater glucose utilization as oxidative fuel. Thus, metformin may have a beneficial effect on countering muscle protein catabolism post-injury by 3 possible mechanisms. The purpose of this study was to determine the effects of metformin on the hypermetabolic response and thus assess any association between glucose intolerance and muscle protein metabolism following severe injury. To accomplish this goal, isotopic tracer methodology, indirect calorimetry, and sequential muscle biopsies were used in combination to measure glucose and muscle protein kinetics in patients following a severe burn. After baseline measurements, metformin was administered in a double-blind, placebo-controlled manner. After 7 days of placebo versus metformin treatment, glucose and muscle protein kinetics were again measured, thereby assessing the influence of metformin on glucose tolerance and muscle protein kinetics in critically ill patients.
MATERIALS AND METHODS

Study Subjects
A total of 16 patients were recruited for study, of which 2 subjects were female. Characteristics of the study subjects are presented in Table 1 and 2. All patients had burns encompassing over 40% of their body surface area and were admitted to the burn intensive care unit within 2 days of their injury. Subjects ranged in age from 23 to 52 years and in weight from 54 to 130 kg. All study subjects had good hemodynamics and adequate urine output on recruitment. Seven study subjects required mechanical ventilation at the time of study entry. Patients were excluded from participation if they were diabetic prior to their burn injury, had renal and liver dysfunction (serum creatinine Ͼ1.5 mg/dL, bilirubin Ͼ3.0 mg/dL), were hypoxic (PaO 2 /FiO 2 Ͻ150) or had lactic acidosis (pH Ͻ7.30, lactate Ͼ5 mmol/L). All patients were treated in a similar manner clinically with early excision of their burn wound and prompt skin grafting. Nutritional support was exclusively enteral (Vivonex TEN; Norvartis Corp, Summit, NJ), initiated within 48 hours following burn injury, and delivered via a nasal-jejunal tube.
Study Protocol
This study was approved by the institutional review board of The University of Texas Medical Branch, Galveston, TX. Informed written consent was obtained from a family member before study. Between 4 and 9 days following their burn injury, all subjects underwent baseline metabolic measurements. The study protocol for these measurements is diagramed in Figure 1 and performed in each patient's burn intensive care unit room. All subjects were receiving enteral nutrition at the time of study, with the desired caloric goal of 1.2 times their resting energy expenditure (REE). Local anesthesia (1% lidocaine) facilitated placement of vascular access catheters into an adjacent femoral artery and vein. After baseline blood sampling, primed continuous infusions of 6,6d 2 glucose (20 mol/kg prime; 0.333 mol/kg/min) and d 5 phenylalanine (2 mol/kg prime; 0.07 mol/kg/min) were given via central venous access and continued for 5 hours. Indirect calorimetry was performed (Delta Trac, Sensormedics, Inc, Anaheim, CA) between the third and fourth hour of study. Leg blood flow was determined by infusion of indocyanine green dye (1 mg/min ϫ 20 minutes) into the femoral artery, with subsequent spectrophotometric analysis of blood drawn simultaneously from the femoral vein and from the peripheral or central vein access. 17 Leg blood flow measurements were standardized for leg volume as assessed by integrating several circumference measurements with the length of the calf, thigh, and foot. After local anesthesia, muscle biopsies were obtained from the vastus lateralis muscle using a Bergstrom needle. These biopsies were performed at the second and fifth hour of study. After 4.3, 4.45, and 5 hours of isotopic infusion, blood was drawn simultaneously from the femoral artery and vein, thus completing the baseline metabolic measurements.
After the initial tracer study, participants were randomized to receive enterally either metformin or placebo in a double-blind fashion. The initial dosage of metformin was On the second day of study, the 850-mg dosage was given twice at a 12-hour interval. Beginning on the third day of study, 850 mg of metformin was given 3 times per day at an 8-hour interval. The 8-hour dosing schedule was continued for the subsequent 5 days of study. This rapidly progressive dosing regimen was adopted from Stumvoll et al 16 in their study assessing the metabolic response of metformin in patients with non-insulin-dependent diabetes mellitus, yet accelerated to expedite a therapeutic response. Blood glucose levels were obtained at a minimum of every 6 hours. Blood glucose values Ͼ220 mg/dL were confirmed by standard laboratory analysis and treated with insulin administered subcutaneously on a sliding-scale basis. An arterial blood gas was analyzed at least daily to screen for acidosis. After 7 days of study participation, the metabolic study protocol utilizing primed, continuous infusions of 6,6d 2 glucose, d 5 phenylalanine, indirect calorimetry, determination of leg blood flow, and muscle biopsies was repeated, thereby quantifying glucose kinetics, muscle protein metabolism, and energy expenditure for each subject before and at the conclusion of 7 days of placebo versus metformin therapy. Insulin use was withheld for at least 6 hours prior to initiating the metabolic study protocol.
Sample Analysis
Blood glucose levels were initially quantified at bedside (AccuData GTS glucose analyzer; Boehringer Mannheim Corp., Indianapolis, IN) and subsequently confirmed on a glucose/lactate 2300 Stat Analyzer (Yellow Springs Instrument Co., Yellow Springs, OH). Isotopic enrichment of plasma glucose was determined by gas chromatography, mass spectrometry (model 5989; Hewlett-Packard Co., Palo Alto, CA) following penta-acetate derivation. 18 Serum insulin concentrations were determined by commercial radioimmunoassay (Diagnostic Products Corp, Los Angeles, CA).
Isotopic enrichment of phenylalanine and the blood concentration of unlabeled phenylalanine were determined by gas chromatography, mass spectrometry (GCMS) using an internal standard method. 18 Blood was collected in ice-cold tubes containing 2 mL of 15% sulfosalicylic acid and 200 L of internal standard ( 13 C phenylalanine). Samples were vortexed and centrifuged. The supernatant was then frozen at Ϫ80°C until processing. After tert-butyl dimethylsialyl derivatization, plasma samples were then analyzed with GCMS (model 5989; Hewlett Packard) using electron impact ionization. The blood concentration of alanine was also determined utilizing an internal standard method with analysis by GCMS.
Muscle biopsies were analyzed for both intracellular and protein-bound amino acid concentration and isotopic enrichment using an internal standard method with analysis by GCMS. 19 To approximately 20 mg of muscle were added 800 L of 14% perchloric acid and 2 L of internal standard. Samples were homogenized, centrifuged, and the supernatant was collected. This procedure was repeated twice more and the pooled supernatant processed identically to the blood samples above using tert-butyl dimethylsialyl derivatization with analysis by GCMS. This method determined the free intracellular concentration and isotopic enrichment for phenylalanine. The remaining muscle pellet was washed repeatedly with saline and absolute ethanol, dried, and then hydrolyzed with 6 N HCl for determination of protein-bound concentration and enrichment. The protein hydrolysate was then passed over a cation exchange column (Dowex AG; BioRad Laboratories, Richmond, CA), dried, esterified, heated, and subsequently analyzed by GCMS as previously described. 20
Calculations
The standard steady-state equation was used for calculating the whole-body rate of appearance for glucose as assessed from a consistent isotopic enrichment from the multiple blood samples obtained during the final 30 minutes of study 18 The whole body rate of appearance (Ra) for phenylalanine was also calculated using the standard equation for isotopic steady state. 18 Ra ϭ (IE infusate/IE arterial plasma) F where: Ra ϭ rate of appearance (umol/kg/min) IE infusate/IE arterial plasma ϭ isotopic enrichment of infusate and arterial blood sample, respectively (tracer/tracee ratio) F ϭ rate of isotopic infusion (mol/kg/min) For each patient, the amount of phenylalanine administered within the enteral feed was subtracted from the calculated Ra to obtain the endogenous rate of appearance for phenylalanine.
The net balance of phenylalanine across the leg was calculated as follows and expressed per 100 mL leg volume: AVNB ϭ (͓Phe͔art Ϫ ͓Phe͔v)LBF where: AVNB ϭ net balance of phenylalanine across the leg (nmol/min/100 mL leg vol) ͓Phe͔art, ͓Phe͔v ϭ concentration of phenylalanine from artery and vein, respectively (nmol/mL) LBF ϭ leg blood flow (mL/min/100 mL leg volume) Thus, a negative net balance reflects the net release of phenylalanine from the limb.
The kinetics of phenylalanine within skeletal muscle were calculated using a 3-pool model as previously described in detail. 22 Since phenylalanine is an essential amino acid in which production from the leg can only come from breakdown of muscle protein, then Fmo for phenylalanine represents the rate of muscle protein breakdown. Likewise, Fom for phenylalanine represents the rate of muscle protein synthesis.
The 3-pool model as discussed above quantifies muscle protein synthesis. However, as an independent measure of muscle protein synthesis, the fractional synthetic rate of muscle protein was determined by quantifying the rate of incorporation of d 5 phenylalanine into muscle over time and calculated as follows 23 : 
Statistics
Student's independent t test was employed for statistical comparison of results between patients given placebo versus metformin. Student's paired t test was used for comparison between baseline and treatment/placebo period mea- 
RESULTS
Of the 16 patients recruited for study, 5 patients served as placebo-treated controls and underwent metabolic assessment at both baseline and after 7 days of receiving placebo ( Table 1 and 2). Eight patients received metformin while undergoing metabolic assessment both at baseline and after 7 days of metformin treatment. Two other subjects underwent an initial metabolic assessment and were then randomized to receive placebo but did not undergo a second metabolic study. Of these 2 control subjects, one patient became septic, developed multiple organ failure and the investigation aborted. The daughter of the other subject, who was also severely burned, died after this subject had received nearly 7 days of placebo. Her second metabolic study was aborted so that she could be discharged from the hospital to attend her daughter's funeral. One other patient underwent an initial metabolic study, was randomized, and received 7 days of metformin. However, during this week interval, his burns had virtually healed, and he was discharged from the hospital without undergoing a second metabolic study.
In examining the demographics of the 13 subjects completing the entire 1-week of study, placebo-and metformin-treated patients were similar in age, weight, and extent of burn (Table 1 and 2). The over 25% reduction in length of hospital stay with metformin treatment was mostly due to a prolonged hospitalization for one placebo control patient who had poor wound healing and required prolonged ventilatory support. In assessing the safety of metformin and screening for adverse events, measures of organ function were compared between groups ( Table 1 and 2). All monitored hemodynamic values were similar between placebo and metformin treatment groups at baseline and remained similar during the investigation. In regard to pulmonary function, 4 of the 5 patients in the placebo group initially required mechanical ventilatory support, with 1 patient successfully extubating during the week of study. In comparison, 2 pa-tients in the metformin group initially required mechanical ventilation, with neither patient extubating during study. Oxygenation (as indexed by PaO 2 /FiO 2 ratio) and pulmonary compliance were similar between metformin/placebo groups, with no overt episodes of hypoxemia or impaired pulmonary compliance in any patient. There was no evidence of any detriment to renal function associated with metformin, as indexed by plasma creatinine and BUN. Likewise, platelet counts and hemoglobin concentrations were similar between metformin-and placebo-treated patients throughout the study. Patients were excluded from study participation if they were acidotic or had elevated lactate concentrations. There was no significant change in the arterial pH or lactate concentrations for the placebo, control patients. There was a 30% increase in plasma lactate concentration for patients receiving metformin; however, arterial pH values did not evidence acidosis.
Control patients had virtually no change in their REE or RQ during the week of receiving placebo (Table 3 ). In contrast, REE and RQ increased in patients receiving metformin. This increase was statistically significant when the REE was indexed by each patient's basal predicted energy expenditure. Nutritional support was similar in terms of both calories and protein intake in the 2 groups of study subjects ( Table 3) .
Plasma glucose values were recorded frequently throughout the week of study (Table 4 ). On average, these plasma glucose concentrations were significantly lower for those patients receiving metformin compared with the placebo-treated controls. Furthermore, 3 of the 5 patients in the placebo group received on average of 14 units per day of insulin. In contrast, only 2 of 8 patients received insulin in the metformin treatment group, with an average daily insulin dose of only 4 units. Irrespective of the differences in exogenous insulin administration, there was a significant reduction in the arterial plasma glucose concentrations for those patients treated with metformin at the time of each metabolic study ( Table 5 ). Metformin treatment was associated with a significant decrease in the rate of endogenous glucose pro- duction, an increase in the rate of glucose clearance, and an increase in rate of glucose oxidation. Arterial insulin concentrations were not statistically different between control and metformin-treated patients. Metformin had a demonstrable anabolic effect on muscle protein metabolism. For example, patients treated with metformin had a significantly less negative net balance of alanine and phenylalanine across the leg (Table 6 ). Measurements of muscle protein kinetics using 3-compartment modeling demonstrated a trend toward increases in muscle protein synthesis (Fom; P ϭ 0.074) for patients given metformin. Placebo-and metformin-treated patients were similar in Fmo (as an index of muscle protein breakdown), as were values of phenylalanine transport. Most notably, there was a significant increase in the fractional synthetic rate of muscle protein in those patients receiving metformin (Fig. 2) . In contrast placebo, control subjects did not have a significant change in the fractional synthetic rate of muscle protein during the week of study.
DISCUSSION
This study reaffirms the apparent effects of metformin on glucose metabolism as reported in previous pilot study. 24 Most notably, metformin decreased endogenous glucose production, increased glucose clearance, and increased glucose oxidation in severely burned adult patients. This influence on glucose metabolism is similar to that seen when metformin is given to patients with diabetes mellitus in whom metformin decreases hepatic glucose production and augments peripheral insulin sensitivity. 14, 16 A new finding in this study was the anabolic affect of metformin on muscle protein as evidenced by both increased fractional synthetic rate of muscle protein and the greater net rate of phenylalanine deposition into the leg. Thus, this study demonstrates an association between improvements in glucose utilization and a reduction in muscle protein catabolism in critically injured, hypermetabolic patients. This association between hyperglycemia and an exacerbation of muscle protein catabolism was previously demonstrated in normal volunteers by Flakoll et al. 25 Using isotopic tracers to quantify protein metabolism, Flakoll et al 25 rigidly controlled insulin availability by simultaneously infusing insulin and somatostatin (ie, to inhibit endogenous insulin production). The rate of glucose administration was then varied to obtain a normal plasma glucose concentration (95 mg/dL) and subsequently hyperglycemia (191 mg/dL). Hyperglycemia was associated with a significant 3-fold increase in the rate of proteolysis without alteration in either leucine oxidation or nonoxidative disposal of leucine, thereby demonstrating a hyperglycemia-induced increase in wholebody protein breakdown. While in the present study metformin appeared to augment muscle protein synthesis in contrast to the decrease in whole-body protein breakdown as evidenced by Flakoll et al, 25 these 2 studies in conjunction provide supportive evidence of a detrimental effect of hyperglycemia on muscle protein kinetics.
As further evidence of a link between hyperglycemia and muscle protein catabolism, we recently reviewed the findings from 29 adult burn patients who served as either nontreated or placebo-treated controls in a variety of prior metabolic investigations. 26 Using the net balance of phenylalanine across the leg as an index of the rate of muscle protein loss and then stratifying each subject by their plasma glucose value at the time of metabolic study, those patients with severe hyperglycemia (n ϭ 7; mean plasma glucose 231 Ϯ 32 mg/dL) had significantly higher arterial concentrations of phenylalanine and a significantly greater net efflux of phenylalanine from the leg compared with those subjects with either normal plasma glucose concentrations (n ϭ 9; mean plasma glucose 109 Ϯ 13 mg/dL) or those with mild hyperglycemia (n ϭ 13; mean plasma glucose 156 Ϯ 17 mg/dL). This association between hyperglycemia and the extent of muscle protein loss in burn patients was especially remarkable, considering that in the 24 hours prior to the metabolic measurements, more insulin had been administered to those patients with hyperglycemia. This finding of continued hyperglycemia despite administration of insulin suggests a heightened resistance to the action of insulin in those patients with the greatest degree of muscle catabolism. Since insulin has a dual influence on both glucose and muscle protein metabolism, this study and other studies suggest that stressinduced resistance to the action of insulin is a probable mechanism underlying this apparent association between glucose intolerance and muscle protein loss. 27 Thus, one possible explanation of the mechanism of action for metformin is that it restores insulin sensitivity in severely injured patients.
There are other possibilities to explain an anabolic action of metformin on muscle. For example, metformin's effect on muscle protein synthesis maybe related to the agent's inhibition of gluconeogenesis. As noted in this study, the efflux of alanine from muscle was decreased in those patients given metformin. Since alanine is the primary amino acid substrate involved in gluconeogenesis, a metformininduced decrease in endogenous glucose production may reduce alanine consumption and thereby reflexively decrease the efflux of alanine from muscle. Since alanine is released from muscle far in excess of its concentration within muscle protein, 28 a diminished metabolic flux of alanine within muscle would presumably reduce the overall catabolism of muscle protein. Intuitively this relationship between gluconeogenesis and the efflux of alanine from muscle would primarily affect the rate of muscle protein breakdown and not the rate of synthesis. Therefore the 3 compartment model findings of this study in which muscle protein breakdown was not demonstrably affected by metformin implies that this mechanism of action may not be the predominant explanation of the observed improvement in muscle protein metabolism with metformin. Furthermore, studies by Wolfe et al 29 have shown no link between changes in gluconeogenesis and alanine flux, thus further discounting this mechanism as a valid explanation for the observed effects of metformin. Another possibility to explain metformin's protein anabolic effect could be related to the metformin-mediated augmentation of peripheral glucose disposal with an associated in-crease in energy availability within muscle. Intuitively this mechanism of action would also have an effect primarily on decreasing the rate of muscle protein breakdown by shifting glucose utilization toward greater oxidation as fuel and thereby reducing as possible the consumption of amino acids as energy substrate. Again since the 3-compartment model kinetics failed to show any substantial alteration in muscle protein breakdown, this possibility seems less likely as the primary means to account for metformin's anabolic effect on muscle protein.
Several recent reports have noted that aggressive "normalization" of plasma glucose concentration with insulin improves outcome of critically ill patients, especially in regard to reducing infectious morbidity. 4 However, such intensive use of insulin is not without concern (ie, insulininduced hypoglycemia) and is fairly labor intensive (ie, frequent mandatory monitoring). Because of its antihyperglycemic properties, metformin may be a viable alternative to insulin in reducing plasma glucose concentrations in critically patients and thereby be of some clinical utility. Furthermore, metformin is effective enterally and is not associated with hypoglycemia 30 ; thus, metformin may be advantageous by diminishing the concern of iatrogenic hypoglycemia and thereby reduce the need for aggressive glucose monitoring. Unfortunately the administration of metformin at the dosage used in this study did not "normalize" plasma glucose concentrations to the same extent as noted in the study by van den Berghe et al. 4 As it is yet unknown to what threshold the plasma glucose concentration must be maintained to optimize clinical outcome, the incomplete normalization of plasma glucose afforded by metformin is of unknown clinical value. One concern for using metformin in critically ill patients is its association with lactic acidosis. 31 Unlike the prior project investigating the use of metformin in burn patients, 24 we observed an increase in the plasma lactate concentration in those patients receiving metformin, yet without any substantial change in the arterial pH. The clinical significance of this accumulation of lactate without acidosis is unclear. We previously showed in septic patients that increased lactate concentrations resulted from an acceleration in glycolysis in excess of glucose oxidation. 32 Since in the current study glucose uptake and oxidation were both increased with metformin, this is a possible explanation for the concurrent increase in lactate. On the other hand, lactate can also increase in critically ill patients as a consequence of tissue ischemia. 33 Therefore, the basis for the increase in lactate needs to be clarified before metformin can be recommended without reservation in the treatment of severely burned patients. One possibility is concurrent treatment with dichloroacetate, which we have previously shown decreases plasma lactate concentrations in burn patients, without adversely affecting muscle protein metabolism. 34 In any case, a more extensive, outcome-directed study would be needed to determine the clinical utility of metformin in critically ill, hypermetabolic patients.
